(TCEs) to transform cancer therapy. Our novel platform generates gamma-delta bispecific T cell engager (bsTCE) therapeutics that activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T cells. Our gamma-delta bsTCEs have demonstrated potent, specific Vg9Vd2 T cell activation and killing of patient-derived tumor cells in preclinical studies.  We expect that activation of adaptive immunity by our approach has the potential to provide durable immune responses with the potential of enhancing patient survival.

Learn More